Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Recommend:
0
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
Recommend :
0
React to this article
Latest news
Date Title
1m ago CALLIDUS SOFTWARE : CallidusCloud Acquires UK-Based Clicktools, Adds Enterprise Survey and CRM Integration Capability to the Award-Winning Lead To Money Suite
3m ago PETROMIN RESOURCES : Update of Private Placement
5m ago Xactly CMO Scott Broomfield Discusses Marketing Automation Revolution at Ad Age Digital
6m ago BLUEKNIGHT ENERGY PARTNERS : Prices Public Offering of Common Units
6m ago iMobie Introduces AnyTrans 4, Giving the Most Complete iOS 8 Content Management Solution
10m ago GAMEHOST : CORRECTION FROM SOURCE/Gamehost Declares Regular Monthly Dividend for September 2014
11m ago BARCLAYS : N.Y. says Barclays move to toss fraud case should be denied
12m ago Britain's audit watchdog revises corporate governance code
13m ago PNM RESOURCES : Board Declares Quarterly Common Stock Dividend
15m ago MICROSOFT : announces board changes and quarterly dividend increase
Latest news
Advertisement
Hot News 
DIXONS CARPHONE : HELPING HANDSET ; Dixons jobs for Phones4u staff in its stores as ex-boss warns of price rises
THALASSA : Revenue Jeopardised By EU Sanctions Against Russia
SPORTECH : Set To Repay GBP93 Million After HMRC Wins Appeal
CRANEWARE : Ups Dividend As Profit Rises In Improving US Market
GLIMCHER REALTY : Other Events (form 8-K)
Most Read News
1h ago ADOBE SYSTEMS : revenue forecast misses, shares slip
10m ago BARCLAYS : N.Y. says Barclays move to toss fraud case should be denied
37m ago Amid coffee rivalry, McDonald's Canada to sell java in grocery stores
1h ago RAYTHEON : House Ways and Means Committee - Hearing
1h ago DELTA AIR LINES : announces Los Angeles-San Antonio nonstop flights, starting in April
Most recommended articles
10m ago BARCLAYS : N.Y. says Barclays move to toss fraud case should be denied
12m ago Britain's audit watchdog revises corporate governance code
31m ago GBP/USD TECHNICAL ANALYSIS : Pound Touches 2-Week High
31m ago USD/CHF TECHNICAL ANALYSIS : Key Support Just Below 0.93
37m ago Amid coffee rivalry, McDonald's Canada to sell java in grocery stores
Dynamic quotes  
ON
| OFF